Healthcare Active Stocks: Arena Pharmaceuticals (NASDAQ:ARNA), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), TherapeuticsMD (NYSEMKT:TXMD), Boston Scientific (NYSE:BSX)

Technology Stocks News 10

Arena Pharmaceuticals, Inc.’s (NASDAQ:ARNA ) shares dropped 9.4% following news that its CEO Jack Lief, has sold around 40% of his stake in the company. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was -5.29% in last session and finished the day at $5.01. Traded volume was 7.44million shares in the last session and the average volume of the stock remained 4.98million shares. The beta of the stock remained -0.41. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) insider ownership is 0.70%.

Bristol-Myers Squibb Co. (NYSE:BMY) announced that the Japanese Ministry of Health, Labor and Welfare has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), and Sunvepra (asunaprevir), a NS3/4A protease inhibitor, providing a new treatment that can lead to cure for many patients in Japan who currently have no treatment options. Bristol-Myers Squibb Co (NYSE:BMY) dropped -0.31 percent to $47.86 Tuesday on volume of 6.87million shares. The intra-day range of the stock was $47.34 to $47.89. Bristol-Myers Squibb Co (NYSE:BMY) has a market capitalization of $79.31billion.

Biotechs Gilead Sciences (NASDAQ:GILD) and Anika Therapeutics (NASDAQ:ANIK) are among just a few stocks in the Spotlight screen that are still hovering near buy points. Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on July 08, 2014 reported a decrease of -0.11% to the closing price of $87.11. Its fifty two weeks range is $53.21 -$88.60. The total market capitalization recorded $133.77billion. The overall volume in the last trading session was 11.73million shares. In its share capital, GILD has 1.54billion outstanding shares.

TherapeuticsMD Inc (NYSEMKT:TXMD) climbed over 17 percent in the current trading session after FBR Capital Markets issued an “Outperform” rating for the  specialty pharmaceutical company with a price target of $34 per share for the stock, in a research report published yesterday. On Tuesday, shares of TherapeuticsMD Inc (NYSEMKT:TXMD) advanced 32.45% to close the day at $5.47. Company return on investment (ROI) is -47.20% and its monthly performance is recorded as 33.74%. TherapeuticsMD Inc (NYSEMKT:TXMD) quarterly revenue growth is 8.53%.

CRT Capital initiates Boston Scientific Corporation (NYSE:BSX) with a Buy and price target of $16 as co’s turnaround is tracking ahead of plan and should be reflected in shares over time. Firm expects stable 3-5% top line growth beginning this year, 10-12% eps growth based on 300bps of margin expansion by 2015 and 30-35% return of capital to shareholders. Boston Scientific Corporation (NYSE:BSX) stock performance was -0.15% in last session and finished the day at $13.00. Traded volume was 9.97million shares in the last session and the average volume of the stock remained 12.67million shares. The beta of the stock remained 1.09. Boston Scientific Corporation (NYSE:BSX) insider ownership is 0.20%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone